JPWO2021119489A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021119489A5
JPWO2021119489A5 JP2022535517A JP2022535517A JPWO2021119489A5 JP WO2021119489 A5 JPWO2021119489 A5 JP WO2021119489A5 JP 2022535517 A JP2022535517 A JP 2022535517A JP 2022535517 A JP2022535517 A JP 2022535517A JP WO2021119489 A5 JPWO2021119489 A5 JP WO2021119489A5
Authority
JP
Japan
Prior art keywords
seq
sequence
receptor
optionally
lilrb1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022535517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506184A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/064607 external-priority patent/WO2021119489A1/en
Publication of JP2023506184A publication Critical patent/JP2023506184A/ja
Publication of JPWO2021119489A5 publication Critical patent/JPWO2021119489A5/ja
Pending legal-status Critical Current

Links

JP2022535517A 2019-12-11 2020-12-11 Lilrb1ベースのキメラ抗原受容体 Pending JP2023506184A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962946888P 2019-12-11 2019-12-11
US62/946,888 2019-12-11
US202063085969P 2020-09-30 2020-09-30
US63/085,969 2020-09-30
PCT/US2020/064607 WO2021119489A1 (en) 2019-12-11 2020-12-11 Lilrb1-based chimeric antigen receptor

Publications (2)

Publication Number Publication Date
JP2023506184A JP2023506184A (ja) 2023-02-15
JPWO2021119489A5 true JPWO2021119489A5 (enrdf_load_stackoverflow) 2023-12-15

Family

ID=74494998

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022535517A Pending JP2023506184A (ja) 2019-12-11 2020-12-11 Lilrb1ベースのキメラ抗原受容体

Country Status (11)

Country Link
US (5) US20230029341A1 (enrdf_load_stackoverflow)
EP (1) EP4073103A1 (enrdf_load_stackoverflow)
JP (1) JP2023506184A (enrdf_load_stackoverflow)
KR (1) KR20220124173A (enrdf_load_stackoverflow)
CN (1) CN115052887A (enrdf_load_stackoverflow)
AU (2) AU2020401315B2 (enrdf_load_stackoverflow)
BR (1) BR112022011399A2 (enrdf_load_stackoverflow)
CA (1) CA3161112A1 (enrdf_load_stackoverflow)
IL (1) IL293716A (enrdf_load_stackoverflow)
MX (1) MX2022006962A (enrdf_load_stackoverflow)
WO (1) WO2021119489A1 (enrdf_load_stackoverflow)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3962527A4 (en) 2019-04-30 2023-11-01 Senti Biosciences, Inc. CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
US20230029341A1 (en) 2019-12-11 2023-01-26 A2 Biotherapeutics, Inc. Nucleic acid encoding lilrb1-based chimeric antigen receptor
WO2021168317A1 (en) * 2020-02-20 2021-08-26 Senti Biosciences, Inc. Inhibitory chimeric receptor architectures
US12286465B2 (en) * 2020-05-28 2025-04-29 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
EP4196493A1 (en) 2020-08-13 2023-06-21 A2 Biotherapeutics, Inc. Gene fusions for control of genetically modified cells
EP4058474B1 (en) 2020-08-20 2024-05-08 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers
EP4100028A4 (en) 2020-08-20 2023-07-26 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF MESOTHELIN-POSITIVE CARCINOMAS
MX2023002017A (es) 2020-08-20 2023-04-28 A2 Biotherapeutics Inc Composiciones y métodos para tratar cánceres positivos para ceacam.
US20220090016A1 (en) * 2020-09-21 2022-03-24 A2 Biotherapeutics, Inc. Engineered immune cells with micro-clusters
CA3207958A1 (en) 2021-02-16 2022-08-25 Julyun OH Compositions and methods for treating her2 positive cancers
WO2023076912A2 (en) * 2021-10-26 2023-05-04 ImmPACT Bio USA Inc. Cd4+ and/or cd8+ cell populations comprising icars for use in treatment therapies
WO2023168455A2 (en) * 2022-03-04 2023-09-07 D2M Biotherapeutics Limited Anti-lilrb1/2 antibodies and uses thereof
WO2023172991A2 (en) * 2022-03-09 2023-09-14 Immpact Bio Usa, Inc. Bicistronic inhibitory chimeric antigen receptor (icar)/activating chimeric antigen receptor (acar) constructs for use in cancer therapies
WO2025085867A1 (en) * 2023-10-20 2025-04-24 A2 Biotherapeutics, Inc. Compositions and methods for treating blood cancers

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
EP3459560B1 (en) 2011-04-08 2021-02-24 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
KR20140127816A (ko) 2012-02-22 2014-11-04 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
MX386060B (es) 2013-03-15 2025-03-18 Memorial Sloan Kettering Cancer Center Composiciones y usos para inmunoterapia.
ES2910004T3 (es) 2013-07-29 2022-05-11 2Seventy Bio Inc Proteínas de señalización de múltiples partes y sus usos
EP3626261A1 (en) 2013-11-21 2020-03-25 UCL Business Ltd Cell
CA2937938A1 (en) 2014-02-04 2015-08-13 Kite Pharma, Inc. Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
CA2945388A1 (en) * 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
US10316094B2 (en) * 2014-10-24 2019-06-11 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance
WO2016075612A1 (en) 2014-11-12 2016-05-19 Rinat Neuroscience Corp. Inhibitory chimeric antigen receptors
AU2015367317A1 (en) 2014-12-17 2017-06-01 Cellectis Inhibitory chimeric antigen receptor (iCAR or N-CAR) expressing non-T cell transduction domain
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN117886949A (zh) 2015-02-24 2024-04-16 加利福尼亚大学董事会 结合触发的转录开关及其使用方法
KR20170137079A (ko) 2015-03-11 2017-12-12 셀렉티스 그것들의 지속을 증가시키기 위한 동종이계 t 세포의 조작 및/또는 환자들 내로 이식 방법들
JP6843062B2 (ja) 2015-03-27 2021-03-17 ユニバーシティ オブ サザン カリフォルニア Car t細胞免疫療法のための新規標的としてのhla−g
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
GB201509413D0 (en) * 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
MA44314A (fr) 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
US20210206826A1 (en) 2015-11-19 2021-07-08 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof
JP7621053B2 (ja) 2015-11-23 2025-01-29 トラスティーズ オブ ボストン ユニバーシティ キメラ抗原受容体に関する方法および組成物
CA3005482A1 (en) 2015-12-02 2017-06-08 Innovative Targeting Solutions Inc. Single variable domain t-cell receptors
KR20220047898A (ko) 2016-03-11 2022-04-19 2세븐티 바이오, 인코포레이티드 게놈 편집 면역 효과기 세포
EP3263595A1 (en) 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
EP3491017A4 (en) * 2016-07-29 2020-04-08 The Board of Regents of The University of Texas System METHODS OF IDENTIFYING ANTIBODIES BLOCKING LILRB RECEPTORS
BR112019006006A2 (pt) 2016-09-28 2019-06-25 Gavish Galilee Bio Appl Ltd molécula de ácido nucleico, vetor, métodos para preparação de um receptor de antígeno quimérico inibidor, para preparar uma célula imune efetora segura, para selecionar um biomarcador personalizado e para tratar o câncer em um paciente com um tumor, célula imune efetora segura, e, combinação de duas ou mais moléculas de ácido nucleico.
CN110582509A (zh) 2017-01-31 2019-12-17 诺华股份有限公司 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
WO2018148454A1 (en) 2017-02-09 2018-08-16 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
CA3059444A1 (en) 2017-04-14 2018-10-18 The General Hospital Corporation Chimeric antigen receptor t cells targeting the tumor microenvironment
GB201707783D0 (en) 2017-05-15 2017-06-28 Autolus Ltd Cell
CA3062727A1 (en) 2017-05-15 2018-11-22 Autolus Limited A cell comprising a chimeric antigen receptor (car)
GB201707779D0 (en) 2017-05-15 2017-06-28 Autolus Ltd Cell
KR102742220B1 (ko) 2017-09-19 2024-12-17 더 유니버시티 오브 브리티쉬 콜롬비아 항-hla-a2 항체 및 그 사용 방법
PL3688155T3 (pl) 2017-09-28 2023-09-11 Immpact-Bio Ltd. Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar)
WO2019090215A2 (en) 2017-11-06 2019-05-09 Monticello Daniel J Dominant negative ligand chimeric antigen receptor systems
JP2021520209A (ja) 2018-04-04 2021-08-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌患者における腫瘍抗原を検出するための診断アッセイ
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
KR20210088559A (ko) 2018-09-28 2021-07-14 임팩트-바이오 리미티드. 암 요법에 사용하기 위한 활성화 항원 수용체 (aCAR)/저해성 키메라 항원 수용체 (iCAR) 쌍의 식별 방법
US20210386781A1 (en) 2018-10-05 2021-12-16 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3632461A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP4010377A4 (en) 2019-08-09 2023-09-06 A2 Biotherapeutics, Inc. CELL SURFACE RECEPTORS THAT RESPOND TO LOSS OF HETEROZYGOSIS
WO2021030153A2 (en) 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
WO2021030182A1 (en) 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Bifunctional single variable domain t cell receptors and uses thereof
CN114585371A (zh) 2019-08-20 2022-06-03 森迪生物科学公司 嵌合抑制性受体
US20220389075A1 (en) 2019-11-12 2022-12-08 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
US20230029341A1 (en) 2019-12-11 2023-01-26 A2 Biotherapeutics, Inc. Nucleic acid encoding lilrb1-based chimeric antigen receptor
WO2021222576A1 (en) 2020-05-01 2021-11-04 A2 Biotherapeutics, Inc. Pag1 fusion proteins and methods of making and using same
AU2021386366A1 (en) 2020-11-24 2023-06-29 A2 Biotherapeutics, Inc. Adoptive cell therapy for treatment of cancer associated with loss of heterozygosity

Similar Documents

Publication Publication Date Title
CN110352198B (zh) Cd133结合剂及其用途
JP7461950B2 (ja) Cd3抗体およびその医薬用途
KR101455447B1 (ko) Muc1* 항체
CN112703013B (zh) Cd3抗原结合片段及其应用
JP2016138129A5 (enrdf_load_stackoverflow)
JPWO2021119489A5 (enrdf_load_stackoverflow)
TWI883026B (zh) 抗dll3嵌合抗原受體及其用途
CN113573728A (zh) 治疗性SIRPα抗体
JP2018518540A5 (enrdf_load_stackoverflow)
CN118852450A (zh) 双特异性抗体组合物及其使用方法
EP3402818A1 (en) Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
CN118176215B (zh) 新型抗l1cam抗体
JP2023524238A (ja) 治療用SIRPα抗体
JP5818003B2 (ja) ヒト型化抗egfr抗体可変領域の高機能性変異体
JP2016529213A5 (enrdf_load_stackoverflow)
JPWO2019152705A5 (enrdf_load_stackoverflow)
JPWO2019204462A5 (enrdf_load_stackoverflow)
EP3802851A1 (en) Materials and methods for treating stress-related disorders and cancer
CN119894930A (zh) 一种双特异性抗体及其应用
JPWO2020163325A5 (enrdf_load_stackoverflow)
WO2024061272A1 (zh) 抗pd-l1抗体及其用途
WO2025072372A1 (en) Car-t cells expressing vegf binding proteins
WO2024260440A1 (zh) 一种能够结合lilrb2的抗体或其抗原结合片段
WO2024114244A1 (zh) 抗cd100抗体及其用途
WO2024078558A1 (zh) 抗cd100抗体及其用途